Cargando…

Personalising laboratory medicine in the ‘real world’: Assessing clinical utility, by clinical indication, of serum total B(12) and Active-B(12)® (holotranscobalamin) in the diagnosis of vitamin B(12) deficiency

BACKGROUND: Assessing the pre- and post-test probability of disease in the context of routine health care is challenging. We wished to study how test performance parameters relating to clinical utility vary by clinical indication in a ‘real-world’ setting. METHODS: The diagnostic accuracy of serum t...

Descripción completa

Detalles Bibliográficos
Autores principales: Murphy, Michael J, Brandie, Fiona, Ebare, Mildred, Harrison, Michelle, Dow, Ellie, Bartlett, William A, Craig, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458683/
https://www.ncbi.nlm.nih.gov/pubmed/33715445
http://dx.doi.org/10.1177/00045632211003605
_version_ 1784571348061782016
author Murphy, Michael J
Brandie, Fiona
Ebare, Mildred
Harrison, Michelle
Dow, Ellie
Bartlett, William A
Craig, David
author_facet Murphy, Michael J
Brandie, Fiona
Ebare, Mildred
Harrison, Michelle
Dow, Ellie
Bartlett, William A
Craig, David
author_sort Murphy, Michael J
collection PubMed
description BACKGROUND: Assessing the pre- and post-test probability of disease in the context of routine health care is challenging. We wished to study how test performance parameters relating to clinical utility vary by clinical indication in a ‘real-world’ setting. METHODS: The diagnostic accuracy of serum total B(12) and Active-B(12)® (holotranscobalamin) was evaluated in a primary care population, using serum methylmalonic acid as the reference standard. We used electronic requesting to establish the clinical indication for each request. Routine requests from primary care for serum total B(12) were included if creatinine was also measured and estimated glomerular filtration rate was at least 60 mL/min/1.73 m(2). RESULTS: Clinical indications included peripheral neuropathy (n = 168), anaemia (n = 168), cognitive decline (n = 125), suspected dietary deficiency (n = 76), other (n = 362). For peripheral neuropathy, the area under the receiver operator curve ± 95% confidence interval (AUC ± CI) was 0.63 (0.54–0.71) (P = 0.002) for total B(12) and 0.68 (0.60–0.77) (P < 0.0001) for Active-B(12)®. For anaemia, AUC ± CI was 0.56 (0.47–0.66) (P = 0.10) for total B(12) and 0.69 (0.59–0.78) (P < 0.0001) for Active-B(12)®. For cognitive decline, AUC ± CI was 0.54 (0.43–0.65) (P = 0.26) for total B(12) and 0.69 (0.58–0.80) (P = 0.0002) for Active-B(12)®. The pre–post-test change in probability of disease varied by clinical indication. CONCLUSION: Combining diagnostic accuracy studies and electronic testing in a ‘real-world’ setting allows clinical utility to be assessed by clinical indication. Wider application of this would permit more personalised laboratory medicine. In this study, diagnostic performance of total B(12) and Active-B(12)® varied across all indications. Active-B(12)® provided better discrimination, but this may have reflected the cut-offs used.
format Online
Article
Text
id pubmed-8458683
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-84586832021-09-24 Personalising laboratory medicine in the ‘real world’: Assessing clinical utility, by clinical indication, of serum total B(12) and Active-B(12)® (holotranscobalamin) in the diagnosis of vitamin B(12) deficiency Murphy, Michael J Brandie, Fiona Ebare, Mildred Harrison, Michelle Dow, Ellie Bartlett, William A Craig, David Ann Clin Biochem Research Articles BACKGROUND: Assessing the pre- and post-test probability of disease in the context of routine health care is challenging. We wished to study how test performance parameters relating to clinical utility vary by clinical indication in a ‘real-world’ setting. METHODS: The diagnostic accuracy of serum total B(12) and Active-B(12)® (holotranscobalamin) was evaluated in a primary care population, using serum methylmalonic acid as the reference standard. We used electronic requesting to establish the clinical indication for each request. Routine requests from primary care for serum total B(12) were included if creatinine was also measured and estimated glomerular filtration rate was at least 60 mL/min/1.73 m(2). RESULTS: Clinical indications included peripheral neuropathy (n = 168), anaemia (n = 168), cognitive decline (n = 125), suspected dietary deficiency (n = 76), other (n = 362). For peripheral neuropathy, the area under the receiver operator curve ± 95% confidence interval (AUC ± CI) was 0.63 (0.54–0.71) (P = 0.002) for total B(12) and 0.68 (0.60–0.77) (P < 0.0001) for Active-B(12)®. For anaemia, AUC ± CI was 0.56 (0.47–0.66) (P = 0.10) for total B(12) and 0.69 (0.59–0.78) (P < 0.0001) for Active-B(12)®. For cognitive decline, AUC ± CI was 0.54 (0.43–0.65) (P = 0.26) for total B(12) and 0.69 (0.58–0.80) (P = 0.0002) for Active-B(12)®. The pre–post-test change in probability of disease varied by clinical indication. CONCLUSION: Combining diagnostic accuracy studies and electronic testing in a ‘real-world’ setting allows clinical utility to be assessed by clinical indication. Wider application of this would permit more personalised laboratory medicine. In this study, diagnostic performance of total B(12) and Active-B(12)® varied across all indications. Active-B(12)® provided better discrimination, but this may have reflected the cut-offs used. SAGE Publications 2021-04-23 2021-09 /pmc/articles/PMC8458683/ /pubmed/33715445 http://dx.doi.org/10.1177/00045632211003605 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Research Articles
Murphy, Michael J
Brandie, Fiona
Ebare, Mildred
Harrison, Michelle
Dow, Ellie
Bartlett, William A
Craig, David
Personalising laboratory medicine in the ‘real world’: Assessing clinical utility, by clinical indication, of serum total B(12) and Active-B(12)® (holotranscobalamin) in the diagnosis of vitamin B(12) deficiency
title Personalising laboratory medicine in the ‘real world’: Assessing clinical utility, by clinical indication, of serum total B(12) and Active-B(12)® (holotranscobalamin) in the diagnosis of vitamin B(12) deficiency
title_full Personalising laboratory medicine in the ‘real world’: Assessing clinical utility, by clinical indication, of serum total B(12) and Active-B(12)® (holotranscobalamin) in the diagnosis of vitamin B(12) deficiency
title_fullStr Personalising laboratory medicine in the ‘real world’: Assessing clinical utility, by clinical indication, of serum total B(12) and Active-B(12)® (holotranscobalamin) in the diagnosis of vitamin B(12) deficiency
title_full_unstemmed Personalising laboratory medicine in the ‘real world’: Assessing clinical utility, by clinical indication, of serum total B(12) and Active-B(12)® (holotranscobalamin) in the diagnosis of vitamin B(12) deficiency
title_short Personalising laboratory medicine in the ‘real world’: Assessing clinical utility, by clinical indication, of serum total B(12) and Active-B(12)® (holotranscobalamin) in the diagnosis of vitamin B(12) deficiency
title_sort personalising laboratory medicine in the ‘real world’: assessing clinical utility, by clinical indication, of serum total b(12) and active-b(12)® (holotranscobalamin) in the diagnosis of vitamin b(12) deficiency
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458683/
https://www.ncbi.nlm.nih.gov/pubmed/33715445
http://dx.doi.org/10.1177/00045632211003605
work_keys_str_mv AT murphymichaelj personalisinglaboratorymedicineintherealworldassessingclinicalutilitybyclinicalindicationofserumtotalb12andactiveb12holotranscobalamininthediagnosisofvitaminb12deficiency
AT brandiefiona personalisinglaboratorymedicineintherealworldassessingclinicalutilitybyclinicalindicationofserumtotalb12andactiveb12holotranscobalamininthediagnosisofvitaminb12deficiency
AT ebaremildred personalisinglaboratorymedicineintherealworldassessingclinicalutilitybyclinicalindicationofserumtotalb12andactiveb12holotranscobalamininthediagnosisofvitaminb12deficiency
AT harrisonmichelle personalisinglaboratorymedicineintherealworldassessingclinicalutilitybyclinicalindicationofserumtotalb12andactiveb12holotranscobalamininthediagnosisofvitaminb12deficiency
AT dowellie personalisinglaboratorymedicineintherealworldassessingclinicalutilitybyclinicalindicationofserumtotalb12andactiveb12holotranscobalamininthediagnosisofvitaminb12deficiency
AT bartlettwilliama personalisinglaboratorymedicineintherealworldassessingclinicalutilitybyclinicalindicationofserumtotalb12andactiveb12holotranscobalamininthediagnosisofvitaminb12deficiency
AT craigdavid personalisinglaboratorymedicineintherealworldassessingclinicalutilitybyclinicalindicationofserumtotalb12andactiveb12holotranscobalamininthediagnosisofvitaminb12deficiency